Literature DB >> 16130897

Establishment and characterization of A novel Philadelphia-chromosome positive chronic myeloid leukemia cell line, TCC-S, expressing P210 and P190 BCR/ABL transcripts but missing normal ABL gene.

Phan Nguyen Thanh Van1, Phan Thi Xinh, Yasuhiko Kano, Katsushi Tokunaga, Yuko Sato.   

Abstract

A novel Philadelphia-chromosome positive (Ph+) cell line, TCC-S, has been established from a patient with Ph+ chronic myeloid leukemia (CML) in the blastic crisis. TCC-S cells were shown to express both P210 and P190 BCR/ABL transcripts by reverse transcriptase-polymerase chain reaction (PCR), although quantitative-PCR revealed that TCC-S cells mainly expressed P210 BCR/ABL transcript. Karyotype analysis revealed several triploid clones which constantly harbored two der(9)del(9) (p12)t(9;22) (q34;qll)s and two del(9) (q21)s. The der(9)del(9) (p12)t(9;22) (q34;q11) is rarely found in other CML cell lines. Moreover, to the best of our knowledge, del(9) (q21) resulting in missing of a restrict region including normal ABL gene has not been found among CML cell lines previously described. Thus, TCC-S cells with only BCR/ABL gene and no normal ABL gene may be a useful tool for functional study of ABL in Ph+ CML.

Entities:  

Mesh:

Year:  2005        PMID: 16130897     DOI: 10.1111/j.1749-0774.2005.tb00054.x

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  16 in total

Review 1.  The molecular biology of chronic myeloid leukemia.

Authors:  M W Deininger; J M Goldman; J V Melo
Journal:  Blood       Date:  2000-11-15       Impact factor: 22.113

2.  A comparison of different metaphase CGH methods for the detection of cryptic chromosome aberrations of defined size.

Authors:  Jacqueline Schoumans; Kate Nielsen; Iben Jeppesen; Britt-Marie Anderlid; Elisabeth Blennow; Karen Brøndum-Nielsen; Magnus Nordenskjöld
Journal:  Eur J Hum Genet       Date:  2004-06       Impact factor: 4.246

3.  p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.

Authors:  F van Rhee; A Hochhaus; F Lin; J V Melo; J M Goldman; N C Cross
Journal:  Blood       Date:  1996-06-15       Impact factor: 22.113

4.  Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction)

Authors:  F Pane; F Frigeri; M Sindona; L Luciano; F Ferrara; R Cimino; G Meloni; G Saglio; F Salvatore; B Rotoli
Journal:  Blood       Date:  1996-10-01       Impact factor: 22.113

5.  New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia.

Authors:  G Saglio; A Guerrasio; C Rosso; A Zaccaria; A Tassinari; A Serra; G Rege-Cambrin; U Mazza; F Gavosto
Journal:  Blood       Date:  1990-11-01       Impact factor: 22.113

6.  No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group.

Authors:  S Miyawaki; M Tanimoto; T Kobayashi; S Minami; J Tamura; E Omoto; K Kuriyama; K Hatake; K Saito; A Kanamaru; H Oh; S Ohtake; N Asou; H Sakamaki; O Yamada; I Jinnai; K Tsubaki; K Takeyama; A Hiraoka; S Matsuda; M Takahashi; C Shimazaki; K Adachi; S Kageyama; R Ohno
Journal:  Int J Hematol       Date:  1999-08       Impact factor: 2.490

7.  A novel leukemia cell line, MR-87, with positive Philadelphia chromosome and negative breakpoint cluster region rearrangement coexpressing myeloid and early B-cell markers.

Authors:  J Okamura; S Yamada; E Ishii; T Hara; H Takahira; J Nishimura; K Yumura; K Kawa-Ha; K Takase; Y Enomoto
Journal:  Blood       Date:  1988-10       Impact factor: 22.113

Review 8.  Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia.

Authors:  H G Drexler; R A MacLeod; C C Uphoff
Journal:  Leuk Res       Date:  1999-03       Impact factor: 3.156

9.  Suppression of cell proliferation and the expression of a bcr-abl fusion gene and apoptotic cell death in a new human chronic myelogenous leukemia cell line, KT-1, by interferon-alpha.

Authors:  K Yanagisawa; H Yamauchi; M Kaneko; H Kohno; H Hasegawa; S Fujita
Journal:  Blood       Date:  1998-01-15       Impact factor: 22.113

10.  Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.

Authors:  Alfonso Quintas-Cardama; Hagop Kantarjian; Moshe Talpaz; Susan O'Brien; Guillermo Garcia-Manero; Srdan Verstovsek; Mary Beth Rios; Kimberly Hayes; Armand Glassman; B Nebiyou Bekele; Xian Zhou; Jorge Cortes
Journal:  Blood       Date:  2004-11-30       Impact factor: 22.113

View more
  4 in total

1.  Native RNA G quadruplex immunoprecipitation (rG4IP) from mammalian cells.

Authors:  Arif A Surani; Cristina Montiel-Duarte
Journal:  STAR Protoc       Date:  2022-05-20

2.  SP1 and RARα regulate AGAP2 expression in cancer.

Authors:  Yegor Doush; Arif A Surani; Amaia Navarro-Corcuera; Stephanie McArdle; E Ellen Billett; Cristina Montiel-Duarte
Journal:  Sci Rep       Date:  2019-01-23       Impact factor: 4.379

3.  Deletion 9p23 to 9p11.1 as sole additional abnormality in a Philadelphia positive chronic myeloid leukemia in blast crisis: a rare event.

Authors:  Abdulsamad Wafa; Manar Asa'ad; Adnan Ikhtiar; Thomas Liehr; Walid Al-Achkar
Journal:  Mol Cytogenet       Date:  2015-08-04       Impact factor: 2.009

4.  Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells.

Authors:  Alena Malyukova; Dorina Ujvari; Elham Yektaei-Karin; Ana Zovko; Harsha S Madapura; Marton Keszei; Noemi Nagy; Kourosh Lotfi; Niclas Björn; Jonas Wallvik; Minori Tamai; Thao T T Nguyen; Koshi Akahane; Takeshi Inukai; Leif Stenke; Daniel Salamon
Journal:  Cell Death Dis       Date:  2021-09-25       Impact factor: 8.469

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.